Virus / Therapies / Genes / Gene / Manufacturing / BioTech / Biotech / Drug / Drugs / Engineering / Boston / Boston blog main / Boston top stories / National blog main / National top stories / New York blog main / Raleigh-Durham blog main / San Francisco blog main / Beta-Thalassemia / Biogen / BlueBird Bio / Brammer Bio / cancer / Catalent / Cell Therapy / clinical trials / David Hallal / EcoR1 Capital / ElevateBio / F2 Ventures / FDA / Gene Therapy / hemophilia / investing / Johnson & Johnson / Life Sciences / Mitch Finer / MPM Capital / Novartis / Paragon Bioservices / Pfizer / Redmile Group / Roche / Samsara BioCapital / startups / UBS Oncology Investment Fund / Venture Capital / Zolgensma

ElevateBio Gets $150M to Grow a Crop of Gene & Cell Therapy Startups

Posted on: May 13, 2019   |   Posted by: Biotech Mag

ElevateBio Gets $150M to Grow a Crop of Gene & Cell Therapy Startups

When a biotech startup is ready to test an experimental therapy it faces a pricey choice: Should it make its drug in-house, or hire a contract manufacturer? The decision is...

Continue reading ...



Other Posts from Biotech Mag